TO-1187
TO-1187 is a selective HDAC6 PROTAC degrader (DC50: 5.81 nM). TO-1187 promotes the ubiquitination and degradation of HDAC6 and can be used in the study of hematological malignancies and solid tumors (Pink: HDAC6 ligand ; Blue: CRBN ligase ligand (HY-41547) ; Black: linker (HY-140212) ).
Product Specifications
UNSPSC
12352005
Target
HDAC; PROTACs
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer; Neurological Disease
Smiles
O=C(C1=CC=C(C=C1)CN(CC2=CN=CC=C2)CC3=CN(N=N3)CCOCCNC4=CC=CC(C(N5C6CCC(NC6=O)=O)=O)=C4C5=O)NO
Molecular Formula
C34H35N9O7
Molecular Weight
681.70
References & Citations
[1]Kollmannsberger C, et al. A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. Oncologist. 2021 Mar;26 (3) :182-e361.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Cereblon; HDAC6
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSH033875-01 20 µg
Recombinant Human LAG-3/CD223 (C-6His-Avi) Biotinylated
Sign In for Pricing
View Details PKSH033875-02 100 µg
Recombinant Human LAG-3/CD223 (C-6His-Avi) Biotinylated
Sign In for Pricing
View Details 
